stock-exchange-911613_1920

Pharma stocks soar after US midterm elections

pharmafile | November 8, 2018 | News story | Business Services, Manufacturing and Production Shares, Stock, Trump, biotech, pharma, stock market 

Despite the threat of a bipartisan pricing plan, pharma stocks have soared after the announcement of the results of the US midterm elections.

While the Republicans retained control of the house, the party lost control of the Senate thus allowing for a slight Democrat majority of 222 in comparison to the GOP’s 196.

However, analysts are taking the result as a win. Andrea Harris, an analyst at Height Capital Markets commented in suggesting although the industry may be concerned about “headline risk ahead […the] Republican Senate and pharma-friendly Democrats will prevent disruptive policy change.”

Advertisement

Meanwhile RBC Capital Markets’ Brian Abrahams suggested that a political stalemate is the most likely situation, as he described the deadlock as a “best-case scenario”. Either way the midterms call into question the future of the pricing plan.

Nevertheless generic drugmakers are most likely to win out overall as the pricing plan promises to boost business for cheaper drugs.

Louis Goss

Related Content

Cellbyte raises $2.75m to fund pharma drug launch platform

Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …

Lilly opens fourth US Gateway Labs site

Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

The Gateway to Local Adoption Series

Latest content